High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma

Gao, Pengxiang; Zou, Kang; Li, Xiao; Zhou, Hongxia; Xu, Xinping; Zeng, Zhenguo; Zhang, Wei

doi:10.1016/j.intimp.2022.108954

Cited by 16 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTGES3, a member of the prostaglandin enzyme family, has been previously reported as a cochaperone of heat shock protein 90 (HSP90) 31 and shown to exert oncogenic effects in lung adenocarcinoma and prostate cancer. 32,33 HSP90AA1, a member of the HSP90 family, is a potential molecular target for cancer treatment. 34 The HSF1-HSPB1 pathway is well known for its role in maintaining cancer cell survival, 35 and HSPB1 has also been shown to be upregulated in preeclampsia.…”

Section: Discussionmentioning

confidence: 99%

“…According to our analysis, PTGES3, HSP90AA1, and HSPB1 are not only DEGs for EMS in the GSE25628 dataset but also downstream targets of HSF1. PTGES3, a member of the prostaglandin enzyme family, has been previously reported as a cochaperone of heat shock protein 90 (HSP90) 31 and shown to exert oncogenic effects in lung adenocarcinoma and prostate cancer 32,33 . HSP90AA1, a member of the HSP90 family, is a potential molecular target for cancer treatment 34 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serum HSF1 is upregulated in endometriosis patients and serves as a potential diagnostic biomarker

Pan

Wan

2023

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Endometriosis (EMS) is a prevalent gynecological condition lacking reliable diagnostic biomarkers. This prospective study aimed to analyze the potential of serum heat shock transcription factor 1 (HSF1) as a diagnostic marker for EMS. Clinical features of 92 EMS patients and 52 controls were recorded, revealing significant differences in dysmenorrhea, dyspareunia, pelvic pain, nulliparity, and CA125 levels. Serum HSF1 was upregulated in EMS patients, with higher levels in American Society for Reproductive Medicine (ASRM) III/IV than ASRM I/II. Receiver operating characteristic curve analysis demonstrated good diagnostic function for serum HSF1 (AUC: 0.857, sensitivity: 91.30%, specificity: 63.46%). Serum HSF1, dysmenorrhea, dyspareunia, and nulliparity were independent risk factors for EMS, while dysmenorrhea and serum HSF1 were independent risk factors for EMS severity. Additionally, the GSE25628 dataset was downloaded from the GEO database for differential analysis of gene expression. The HSF1 downstream target genes PTGES3, HSP90AA1, and HSPB1 showed significant differential expression in EMS, suggesting their involvement in the regulatory mechanism of HSF1 in EMS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Serum HSF1 is upregulated in endometriosis patients and serves as a potential diagnostic biomarker

Pan

Wan

2023

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…PFKP, involved in metabolism, is a suggested oncogene in lung cancer [ 78 ]. PTGES3 correlates with poor patient prognosis and immune infiltrates in lung adenocarcinoma [ 79 ] and is an oncogenic driver within a 10-gene metabolic panel in NSCLC [ 80 ]. Overall, the literature supports that the 10 hub genes ( Table 7 ) identified in this study are potential oncogenes in NSCLC.…”

Section: Discussionmentioning

confidence: 99%

Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks

Guo

2022

Biomolecules

View full text Add to dashboard Cite

There are currently no accurate biomarkers for optimal treatment selection in early-stage non-small cell lung cancer (NSCLC). Novel therapeutic targets are needed to improve NSCLC survival outcomes. This study systematically evaluated the association between genome-scale regulatory network centralities and NSCLC tumorigenesis, proliferation, and survival in early-stage NSCLC patients. Boolean implication networks were used to construct multimodal networks using patient DNA copy number variation, mRNA, and protein expression profiles. T statistics of differential gene/protein expression in tumors versus non-cancerous adjacent tissues, dependency scores in in vitro CRISPR-Cas9/RNA interference (RNAi) screening of human NSCLC cell lines, and hazard ratios in univariate Cox modeling of the Cancer Genome Atlas (TCGA) NSCLC patients were correlated with graph theory centrality metrics. Hub genes in multi-omics networks involving gene/protein expression were associated with oncogenic, proliferative potentials and poor patient survival outcomes (p < 0.05, Pearson’s correlation). Immunotherapy targets PD1, PDL1, CTLA4, and CD27 were ranked as top hub genes within the 10th percentile in most constructed multi-omics networks. BUB3, DNM1L, EIF2S1, KPNB1, NMT1, PGAM1, and STRAP were discovered as important hub genes in NSCLC proliferation with oncogenic potential. These results support the importance of hub genes in NSCLC tumorigenesis, proliferation, and prognosis, with implications in prioritizing therapeutic targets to improve patient survival outcomes.

show abstract

“…Typically, non-small cell lung cancer (NSCLC) occupies 80% of lung cancer cases [ 31 ]. Recently, great progress has been made in identifying novel diagnostic and prognostic biomarkers for lung cancer, including RBR E3 ubiquitin ligase [ 32 ], prostaglandin E synthase 3 (PTGES3) [ 33 ], fibroblast activation protein (FAP) [ 34 ], checkpoint inhibitor immunotherapy targeting programmed cell death 1 (PD1), and programmed death ligand 1 (PDL1) pathways [ 35 , 36 ]. However, the 5-year overall survival rate of lung cancer remains low among all the cancer types, and its high mortality can be ascribed to the fact that most patients are diagnosed at an advanced stage and the treatment options are thereby limited, with a 5-year survival rate of only 4% [ 37 ].…”

Section: Mirnas and Cancer Diagnosis And Prognosismentioning

confidence: 99%

Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021

Sun

Zhao

Wang

et al. 2022

IJMS

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small non-coding RNAs (ncRNAs) about 22 nucleotides in size, which play an important role in gene regulation and are involved in almost all major cellular physiological processes. In recent years, the abnormal expression of miRNAs has been shown to be associated with human diseases including cancer. In the past ten years, the link between miRNAs and various cancers has been extensively studied, and the abnormal expression of miRNAs has been reported in various malignant tumors, such as lung cancer, gastric cancer, colorectal cancer, liver cancer, breast cancer, and prostate cancer. Due to the high malignancy grade of these cancers, it is more necessary to develop the related diagnostic and prognostic methods. According to the study of miRNAs, many potential cancer biomarkers have been proposed for the diagnosis and prognosis of diseases, especially cancer, thus providing a new theoretical basis and perspective for cancer screening. The use of miRNAs as biomarkers for diagnosis or prognosis of cancer has the advantages of being less invasive to patients, with better accuracy and lower price. In view of the important clinical significance of miRNAs in human cancer research, this article reviewed the research status of miRNAs in the above-mentioned cancers in 2021, especially in terms of diagnosis and prognosis, and provided some new perspectives and theoretical basis for the diagnosis and treatment of cancers.

show abstract

High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma

Cited by 16 publications

References 24 publications

Serum HSF1 is upregulated in endometriosis patients and serves as a potential diagnostic biomarker

Serum HSF1 is upregulated in endometriosis patients and serves as a potential diagnostic biomarker

Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks

Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021

Contact Info

Product

Resources

About